Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.4K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.4K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.9K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interpreting apparent differences among the major colchicine trials for cardiovascular prevention: a descriptive compatibility analysis.

American heart journal·2026
Same author

DOAC Score Among Patients Receiving Vitamin K Antagonists.

American heart journal·2026
Same author

Patient-Centered Evaluation of Anticoagulation in Atrial Fibrillation.

NEJM evidence·2026
Same author

Major adverse cardiovascular and bleeding outcomes in paroxysmal vs. non-paroxysmal atrial fibrillation: an individual patient-level data analysis of a large cohort of patients from the COMBINE-AF.

European journal of internal medicine·2026
Same author

Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus Warfarin.

Circulation·2026
Same author

One-year mortality among adults with advanced HIV in sub-Saharan Africa: a systematic review and meta-analysis.

AIDS (London, England)·2025

Related Experiment Video

Updated: Feb 2, 2026

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
07:08

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

Published on: September 5, 2017

8.9K

Anticoagulant-Related Nephropathy.

Sergey Brodsky1, John Eikelboom2, Lee A Hebert3

  • 1Renal and Transplant Pathology Laboratory, Department of Pathology and.

Journal of the American Society of Nephrology : JASN
|November 14, 2018
PubMed
Summary

Anticoagulant-related nephropathy (ARN) is a newly identified kidney injury. New analysis suggests ARN is not rare in patients taking oral anticoagulants for atrial fibrillation.

Keywords:
chronic kidney diseasenephropathyrenal biopsy

More Related Videos

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

947
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.4K

Related Experiment Videos

Last Updated: Feb 2, 2026

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
07:08

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

Published on: September 5, 2017

8.9K
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

947
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.4K

Area of Science:

  • Nephrology
  • Hematology
  • Pharmacology

Background:

  • Anticoagulant-related nephropathy (ARN) is a recently recognized cause of acute kidney injury (AKI).
  • It is characterized by glomerular hemorrhage due to overanticoagulation, with tubules filled with red cells and casts on biopsy.
  • Despite widespread oral anticoagulant use since the 1950s, ARN was only recently discovered, implying rarity.

Purpose of the Study:

  • To review the discovery and confirmation of ARN.
  • To present an animal model of ARN.
  • To analyze existing data and provide recommendations for diagnosis and management.

Main Methods:

  • Review of the literature on ARN discovery and confirmation.
  • Description of a developed animal model for ARN.
  • Analysis of
  • renal events
  • from post hoc analyses of anticoagulation trials and retrospective database studies.

Main Results:

  • The initial discovery of ARN has been validated by numerous independent researchers.
  • Analysis of existing clinical data suggests ARN may not be a rare complication in anticoagulated patients with atrial fibrillation.
  • Significant biases exist in post hoc and retrospective analyses, highlighting the need for prospective studies.

Conclusions:

  • ARN is an important consideration in patients on oral anticoagulation.
  • Further prospective research is crucial to accurately determine the incidence and risk factors for ARN.
  • Recommendations for diagnosis and management are provided based on current evidence.